Overview

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

This phase II MATCH treatment trial evaluates the effectiveness of osimertinib (AZD9291) in treating patients with cancer that has certain genetic changes called EGFR mutations. Osimertinib is in a class of medications called kinase inhibitors. It works by blocking the action of mutant forms of the EGFR protein, which play a key role in tumor cell growth. Osimertinib may cause tumor cell death and inhibit tumor growth in EGFR-overexpressing tumor cells, thereby stopping or slowing the spread of tumor cells.

Phase:

PHASE2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Biopsy
osimertinib
Specimen Handling
X-Rays